Qlucore Receives EUR 0.5 Million EU Payment

QCOREPressemeddelelse23.06.2026, 19.20

Qlucore, a leading provider of software for precision cancer diagnostics, has now received the third payment of approximately EUR 0.5 million under its previously awarded EU grant.

The total grant amounts to EUR 2.5 million and is distributed across four installments. The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer.

About Qlucore

Qlucore develops AI‑based software that enables more accurate diagnostics and a more cost‑efficient healthcare system. Through the company’s precision medicine solutions, tens of thousands of genetic data points are transformed into clear decision‑making support, making it possible to deliver the right treatment to each patient at the right time.

The first diagnostic test – for pediatric blood cancer – has been approved for sale within the EU. Additional tests, including for lung cancer, adult blood cancer, and bladder cancer, are under development. These products target large and growing markets with significant medical and economic needs. The goal is to improve treatment outcomes, reduce human suffering, and lower healthcare costs.

In addition to its diagnostics portfolio, Qlucore offers Qlucore Omics Explorer, an established software platform for advanced data analysis used by researchers and pharmaceutical companies worldwide. The company has customers in about 20 countries, sales offices in Europe and North America, and distributors across several Asian markets.

Qlucore is listed on Nasdaq First North Growth market. More information: www.qlucore.com